Compare NPCE & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPCE | ACRS |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.2M | 529.9M |
| IPO Year | 2021 | 2015 |
| Metric | NPCE | ACRS |
|---|---|---|
| Price | $12.35 | $3.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $20.00 | $10.09 |
| AVG Volume (30 Days) | 94.2K | ★ 3.9M |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.03 | ★ 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,986,000.00 | $1,683,000.00 |
| Revenue This Year | $0.36 | N/A |
| Revenue Next Year | $22.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.13 | N/A |
| 52 Week Low | $9.22 | $2.10 |
| 52 Week High | $19.60 | $6.60 |
| Indicator | NPCE | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 45.37 |
| Support Level | N/A | $3.18 |
| Resistance Level | $15.26 | $4.67 |
| Average True Range (ATR) | 0.57 | 0.25 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 15.06 | 86.34 |
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.